secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kymera Therapeutics, Inc. (KYMR)
CIK:        0001815442
Form:       8-K
Filed at:   2022-12-14T23:59:59+00:00
Accession:  0001193125-22-304456
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kymera provides clinical update on KT-474 Phase 1 Part C in HS & AD; oncology pipeline update
--------------------------------------------------------------------------------

- Held virtual investor event to present Part C Phase 1 data for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis.
- Also discussed updates on the company's oncology pipeline programs.
- Full presentation furnished as Exhibit 99.1; no specific numerical results disclosed in the filing text.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522304456/0001193125-22-304456-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815442/000119312522304456/d313389d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-304456

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer